HomeClinical TopicsFDA approves new drug for schizophrenia and new drug for lung cancer

FDA approves new drug for schizophrenia and new drug for lung cancer

On July 13, the U.S. Food and Drug Administration (FDA) approved

  • Rexulti (brexpiprazole) to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Read more
  • Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors harbor specific types of epidermal growth factor receptor gene mutations, as detected by an FDA-approved test. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Couple talking to NP

Getting Covid Vaccine Won’t Hurt Pregnancy Chances; Getting Covid Could

Couples planning a pregnancy might be relieved to know that getting a Covid vaccine does not hurt their odds of conceiving, according to the...